Axsome's Alzheimer's-related drug shows mixed results in late-stage studies (updated)

Axsome Therapeutics

30/12/2024 12:28

(Rewrites paragraph 1, adds detail on trials in paragraphs 2-5)
       Dec 30 (Reuters) - Axsome Therapeutics  AXSM.O  said on
Monday its experimental drug to treat agitation related to
Alzheimer's disease succeeded in one of the two late-stage
studies and failed to meet the main goal of the second trial.
    Shares of the drug developer, which was testing the
treatment, AXS-05, dropped 12% in premarket trading.
    The agitation is a symptom that causes emotional distress as
well as verbal and physical aggressiveness.
    The treatment significantly delayed the time to relapse in
agitation as measured on a disease severity scale in one study,
but did not demonstrate statistical significance in delaying
agitation in another late-stage trial.
    AXS-05 was safe and well tolerated in both the studies, the
company said.
    

 (Reporting by Sneha S K; Editing by Shilpi Majumdar)
 ((Sneha.SK@thomsonreuters.com;))